Top 5 Most Read RNS's on Vox Markets for Monday 22nd August 2022
Episode 842, Aug 22, 2022, 07:51 AM
Top 5 Most Read RNS's on Vox Markets for Monday 22nd August 2022
5. Dev Clever Holdings - Funding Facility
Dev Clever have obtained A Three-Year Unsecured Convertible Funding Facility With Riverfort Global Opportunities For Up To $30 Million
(Click here to read the RNS)
4. Dev Clever Holdings - Annual Financial Report.
Total revenue up 486% to £7.36 million (2020: £1.25 million), reflecting revenue arising from the Aldebaron agreement.
Adjusted EBITDA profit was £1.30 million (2020: loss £0.79m).
The loss before tax was £2.54 million (2020: £1.06 million).
(Click here to read the RNS)
3. Genedrive PLC - NICE includes CYP2C19-ID Kit in new programme.
Genedrive plc announces that the UK's National Institute for Health and Clinical Excellence ('NICE') has commenced an evaluation of CYP2C19 genotype testing for Clopidogrel treatment, via a new NICE Diagnostics Assessment Programme ('DAP'). Genedrive's CYP2C19 ID Kit, currently in development, has been included in the assessment. Both of genedrive's new emergency Point of Care genetic screening tests are now included in new NICE reviews, following the MT-RNR1 DAP announcement on 16 June 2022.
(Click here to read the RNS)
2. Open Orphan PLC - £10.4m contract with existing Big Pharma client.
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that hVIVO, a subsidiary of Open Orphan, has signed a £10.4m contract with an existing top 5 global pharmaceutical client to manufacture a new batch of H1N1 influenza challenge virus, leveraging off an existing in-house generated challenge model, and to conduct a human challenge trial to test the client's antiviral product.
(Click here to read the RNS)
1. Cineworld Group plc - Response to media speculation
The strategic options through which Cineworld may achieve its restructuring objectives include a possible voluntary Chapter 11 filing in the United States and associated ancillary proceedings in other jurisdictions as part of an orderly implementation process. Cineworld is in discussions with many of its major stakeholders including its secured lenders and their legal and financial advisers.
(Click here to read the RNS)
5. Dev Clever Holdings - Funding Facility
Dev Clever have obtained A Three-Year Unsecured Convertible Funding Facility With Riverfort Global Opportunities For Up To $30 Million
(Click here to read the RNS)
4. Dev Clever Holdings - Annual Financial Report.
Total revenue up 486% to £7.36 million (2020: £1.25 million), reflecting revenue arising from the Aldebaron agreement.
Adjusted EBITDA profit was £1.30 million (2020: loss £0.79m).
The loss before tax was £2.54 million (2020: £1.06 million).
(Click here to read the RNS)
3. Genedrive PLC - NICE includes CYP2C19-ID Kit in new programme.
Genedrive plc announces that the UK's National Institute for Health and Clinical Excellence ('NICE') has commenced an evaluation of CYP2C19 genotype testing for Clopidogrel treatment, via a new NICE Diagnostics Assessment Programme ('DAP'). Genedrive's CYP2C19 ID Kit, currently in development, has been included in the assessment. Both of genedrive's new emergency Point of Care genetic screening tests are now included in new NICE reviews, following the MT-RNR1 DAP announcement on 16 June 2022.
(Click here to read the RNS)
2. Open Orphan PLC - £10.4m contract with existing Big Pharma client.
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that hVIVO, a subsidiary of Open Orphan, has signed a £10.4m contract with an existing top 5 global pharmaceutical client to manufacture a new batch of H1N1 influenza challenge virus, leveraging off an existing in-house generated challenge model, and to conduct a human challenge trial to test the client's antiviral product.
(Click here to read the RNS)
1. Cineworld Group plc - Response to media speculation
The strategic options through which Cineworld may achieve its restructuring objectives include a possible voluntary Chapter 11 filing in the United States and associated ancillary proceedings in other jurisdictions as part of an orderly implementation process. Cineworld is in discussions with many of its major stakeholders including its secured lenders and their legal and financial advisers.
(Click here to read the RNS)